
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is des... Actuate Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We are developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B. We believe that the blockade of GSK-3B signaling ultimately results in the death of the cancer cells and the regulation of anti-tumor immunity. We have exclusively licensed a portfolio of GSK-3 inhibitors developed in a collaboration between the University of Illinois-Chicago (UIC) and Northwestern University (NU). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.19 | 2.53333333333 | 7.5 | 7.99 | 6.72 | 15451 | 7.74719427 | CS |
4 | -2.37 | -23.5586481113 | 10.06 | 10.8 | 6.72 | 19748 | 8.51910161 | CS |
12 | -0.42 | -5.17879161529 | 8.11 | 11.1261 | 6.27 | 46341 | 8.18949407 | CS |
26 | -0.36 | -4.47204968944 | 8.05 | 11.1261 | 5.51 | 46726 | 8.13468485 | CS |
52 | 2.69 | 53.8 | 5 | 11.1261 | 5 | 24534 | 8.16560537 | CS |
156 | 2.69 | 53.8 | 5 | 11.1261 | 5 | 8091 | 8.16560537 | CS |
260 | 2.69 | 53.8 | 5 | 11.1261 | 5 | 5531 | 8.16560537 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions